prednisone has been researched along with olaparib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Serena Ricci, C; Tufoni, M; Zaccherini, G | 1 |
| Fong, L; Nicholson, LT | 1 |
| Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P | 1 |
| Antonarakis, ES; Begbie, SD; Chiu, KY; De Santis, M; Fong, PC; Gafanov, RA; Goh, JC; Greil, R; Huang, YH; Kim, J; Kolinsky, MP; Kramer, G; Lee, JL; Massari, F; McDermott, R; Mehra, N; Park, SH; Poehlein, CH; Qiu, P; Retz, M; Rey, F; Rosenbaum, E; Roubaud, G; Sade, JP; Sala-Gonzalez, N; Shin, SJ; Sumitomo, M; Suzuki, H; Yanez, P; Yu, EY; Zhang, J | 1 |
| Fallara, G; Malavaud, B; Martini, A; Ploussard, G | 1 |
2 trial(s) available for prednisone and olaparib
| Article | Year |
|---|---|
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone | 2022 |
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Disease-Free Survival; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
3 other study(ies) available for prednisone and olaparib
| Article | Year |
|---|---|
A Case of Immune-Mediated Liver Injury Induced by Olaparib.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; Humans; Liver; Liver Function Tests; Middle Aged; Phthalazines; Piperazines; Prednisone | 2018 |
Immune Checkpoint Inhibition in Prostate Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Prednisone; Programmed Cell Death 1 Receptor; Prostatic Neoplasms | 2020 |
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Phthalazines; Piperazines; Prednisone; Prostatic Neoplasms, Castration-Resistant | 2023 |